JP2022172244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022172244A5 JP2022172244A5 JP2022137454A JP2022137454A JP2022172244A5 JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5 JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hcv
- genotype
- hcv genotype
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (11)
- 以下を含む、免疫原性組成物：
（ａ）第１のＣ型肝炎ウイルス（ＨＣＶ）遺伝子型からのＨＣＶ Ｅ１ポリペプチド、Ｅ２ポリペプチド、またはＥ１／Ｅ２ヘテロ二量体ポリペプチド、ここで、該第１のＨＣＶ遺伝子型は遺伝子型１型である；
（ｂ）第２のＨＣＶ遺伝子型からのＨＣＶ Ｅ１ポリペプチド、Ｅ２ポリペプチド、またはＥ１／Ｅ２ヘテロ二量体ポリペプチド、ここで、該第２のＨＣＶ遺伝子型は遺伝子型３型である；
（ｃ）薬学的に許容される賦形剤；および
（ｄ）免疫刺激量のアジュバント、
ここで、該組成物は、ＨＣＶ遺伝子型１型およびＨＣＶ遺伝子型３型以外の遺伝子型のＨＣＶ Ｅ１／Ｅ２ヘテロ二量体ポリペプチド、Ｅ１ポリペプチド、またはＥ２ポリペプチドを含まない。 - 前記Ｅ１ポリペプチドが可溶性Ｅ１ポリペプチドである、請求項１に記載の免疫原性組成物。
- 前記Ｅ１ポリペプチドが全長Ｅ１ポリペプチドである、請求項１に記載の免疫原性組成物。
- 前記Ｅ２ポリペプチドが可溶性Ｅ２ポリペプチドである、請求項１に記載の免疫原性組成物。
- 前記Ｅ２ポリペプチドが全長Ｅ２ポリペプチドである、請求項１に記載の免疫原性組成物。
- （ｉ）ＨＣＶ遺伝子型１型のＥ１／Ｅ２ヘテロ二量体ポリペプチド；及びＨＣＶ遺伝子型３型のＥ１／Ｅ２ヘテロ二量体ポリペプチド；または
（ｉｉ）ＨＣＶ遺伝子型１型の可溶性Ｅ２ポリペプチド；およびＨＣＶ遺伝子型３型の可溶性Ｅ２ポリペプチド；または
（ｉｉｉ）ＨＣＶ遺伝子型１型の可溶性Ｅ１ポリペプチドおよび可溶性Ｅ２ポリペプチド；ならびに、ＨＣＶ遺伝子型３型の可溶性Ｅ１ポリペプチドおよび可溶性Ｅ２ポリペプチド
を含む、請求項１に記載の免疫原性組成物。 - 前記アジュバントが、ＭＦ５９、ミョウバン、モノホスホリル脂質Ａ、コレステロール、Ｑｕｉｌ Ａ、またはＣｐＧオリゴヌクレオチドを含む、請求項１に記載の免疫原性組成物。
- 前記ＨＣＶ Ｅ１ポリペプチド、Ｅ２ポリペプチド、またはＥ１/Ｅ２ヘテロ二量体ポリペプチドが少なくとも９０％純粋である、請求項1に記載の免疫原性組成物。
- 個体においてＣ型肝炎ウイルス（ＨＣＶ）に対する免疫応答を誘導する方法において使用するための請求項１～８のいずれか１項に記載の組成物であって、該免疫応答がＨＣＶ遺伝子型１型および３型に対する中和抗体の産生を含む、該組成物。
- 筋肉内に投与される、請求項９に記載の組成物。
- 前記個体が静注薬物使用者である、請求項９に記載の組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823712P | 2013-05-15 | 2013-05-15 | |
| US61/823,712 | 2013-05-15 | ||
| US201361887229P | 2013-10-04 | 2013-10-04 | |
| US61/887,229 | 2013-10-04 | ||
| JP2021001926A JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001926A Division JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022172244A JP2022172244A (ja) | 2022-11-15 |
| JP2022172244A5 true JP2022172244A5 (ja) | 2023-07-28 |
Family
ID=54054625
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2022137454A Pending JP2022172244A (ja) | 2013-05-15 | 2022-08-31 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210145963A9 (ja) |
| EP (2) | EP3689375A1 (ja) |
| JP (4) | JP2016520077A (ja) |
| CN (2) | CN105263517B (ja) |
| AU (3) | AU2014385320B2 (ja) |
| CA (1) | CA2909586C (ja) |
| CL (1) | CL2015003333A1 (ja) |
| HK (1) | HK1216395A1 (ja) |
| WO (1) | WO2015132619A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060857A1 (en) * | 2015-10-08 | 2017-04-13 | The Governors Of The University Of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| WO2018055535A2 (en) * | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
| US10881726B2 (en) | 2016-10-11 | 2021-01-05 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
| EP3765075A4 (en) * | 2018-03-16 | 2021-12-08 | The Governors of the University of Alberta | PEPTIDIC COMPOSITIONS OF THE HEPATITIS C VIRUS AND THEIR USE PROCEDURES |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
| EP1175912A1 (en) | 1993-03-23 | 2002-01-30 | SmithKline Beecham Biologics SA | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU3241095A (en) | 1994-07-29 | 1996-03-04 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| WO1998016247A1 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| JP5087758B2 (ja) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用 |
| EP0980434B1 (en) | 1997-05-06 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Intracellular production of hepatitis c e2 truncated polypeptid |
| DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| EP0986572B2 (en) | 1997-06-06 | 2007-06-13 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
| MY125387A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
| EP2322210A1 (en) | 1999-04-19 | 2011-05-18 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| CA2383413A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| WO2001021152A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| WO2003002065A2 (en) * | 2001-06-29 | 2003-01-09 | Chiron Corporation | Hcv e1e2 vaccine compositions |
| US7348011B2 (en) * | 2005-06-10 | 2008-03-25 | Sudershan Biotech Ltd. | Hepatitis C virus vaccine |
| WO2007041432A2 (en) | 2005-09-30 | 2007-04-12 | Novartis Vaccines And Diagnostics, Inc. | Cross-neutralization of hcv with recombinant proteins |
| WO2009061739A1 (en) * | 2007-11-06 | 2009-05-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralization of hcv |
| WO2014060851A2 (en) * | 2012-10-05 | 2014-04-24 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
-
2014
- 2014-05-15 JP JP2016513459A patent/JP2016520077A/ja not_active Withdrawn
- 2014-05-15 EP EP19215826.9A patent/EP3689375A1/en not_active Withdrawn
- 2014-05-15 US US14/783,699 patent/US20210145963A9/en not_active Abandoned
- 2014-05-15 CN CN201480027001.3A patent/CN105263517B/zh active Active
- 2014-05-15 CA CA2909586A patent/CA2909586C/en active Active
- 2014-05-15 WO PCT/IB2014/001972 patent/WO2015132619A1/en active Application Filing
- 2014-05-15 AU AU2014385320A patent/AU2014385320B2/en active Active
- 2014-05-15 CN CN202110252076.3A patent/CN112999344A/zh active Pending
- 2014-05-15 EP EP14884476.4A patent/EP2996718B1/en active Active
-
2015
- 2015-11-13 CL CL2015003333A patent/CL2015003333A1/es unknown
-
2016
- 2016-04-18 HK HK16104408.0A patent/HK1216395A1/zh unknown
-
2019
- 2019-05-08 JP JP2019087976A patent/JP2019142962A/ja not_active Withdrawn
-
2020
- 2020-01-10 AU AU2020200216A patent/AU2020200216A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021001926A patent/JP2021059596A/ja active Pending
-
2022
- 2022-02-04 AU AU2022200747A patent/AU2022200747A1/en active Pending
- 2022-03-23 US US17/702,231 patent/US20230098265A1/en not_active Abandoned
- 2022-08-31 JP JP2022137454A patent/JP2022172244A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022172244A5 (ja) | ||
| JP2019519252A5 (ja) | ||
| JP2017515508A5 (ja) | ||
| JP2003526662A5 (ja) | ||
| WO2004011650A2 (en) | Antigens encoded by alternative reading frame from pathogenic viruses | |
| JP2012503011A5 (ja) | 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物 | |
| JP2010500399A5 (ja) | ||
| JP2003526673A5 (ja) | ||
| JP2004518631A5 (ja) | ||
| JP2008514203A5 (ja) | ||
| Encke et al. | DNA vaccines | |
| JP2014523878A5 (ja) | ||
| JP2009501001A5 (ja) | ||
| JP2008539164A5 (ja) | ||
| JP2019142962A5 (ja) | ||
| JP2010530362A5 (ja) | ||
| JP2009501012A5 (ja) | ||
| JP2004527524A5 (ja) | ||
| Noordeen | Hepatitis B virus infection: An insight into infection outcomes and recent treatment options | |
| JP2022071130A5 (ja) | ||
| JP2006502228A5 (ja) | ||
| JP2003508409A (ja) | 慢性ウイルス感染に対するペプチド混合物及びワクチン | |
| JP2007504112A5 (ja) | ||
| BRPI0414026A (pt) | composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b | |
| WO2006024240A2 (es) | Composición vacunal contra el virus de la hepatitis c. |